First quarter loss widens for Damora Therapeutics (DMRA)

Damora Therapeutics (DMRA) reported first quarter results that drew attention, with a net loss of US$27.78 million for the period ended March 31, 2026, compared with US$2.53 million a year earlier.

The share price has been volatile, with a 1 day share price return of 1.77% and year to date share price return of 15.95%. The 1 year total shareholder return is very large, but longer term total shareholder returns over 3 and 5 years are sharply lower, suggesting momentum has picked up recently after a weaker multi year stretch.

If Damora’s swings have your attention, this could be a good moment to see how other high growth stories are trading and compare them using our screener of 34 healthcare AI stocks.

After a sharp widening in quarterly losses but a very large 1 year return and a market value of about US$1.50b, investors now face a simple question: is Damora undervalued, or is expected future growth already in the price?

Price to book of 4x: Is it justified?

On a P/B of 4x, Damora trades above the wider US Biotechs industry but slightly below its closest peer group, which sends a mixed valuation signal at $25.30.

P/B compares the market value of the company to its accounting book value. It is often used for biopharmaceutical stocks that are still loss making and have limited current revenue. For Damora, this makes the balance sheet and asset base an important reference point, because there is no current profit stream to support earnings-based metrics.

Relative to similar companies, Damora is described as good value on a P/B of 4x versus a 4.5x peer average. This suggests investors are not assigning a premium to its equity compared with that closer peer set. However, when the comparison widens to the broader US Biotechs industry at 2.4x, the same 4x P/B looks expensive, implying the stock carries a higher valuation than many other biotech stocks based on book value alone.

This tension between a lower multiple than direct peers and a higher multiple than the broader industry is important, because it hints that investors are paying up versus the sector overall while still pricing Damora slightly below its immediate comparison group.

Result: Price-to-book of 4x (ABOUT RIGHT)

However, investors still need to weigh the widening net loss of US$235.09 million and zero reported revenue, both of which increase execution risk for Damora’s pipeline.

Next Steps

Mixed signals on losses, valuation, and recent returns can feel difficult to balance. Move quickly from headline impressions to the underlying details by weighing the 1 key reward and 5 important warning signs.

Looking for more investment ideas?

Damora might be on your radar, but some of the most interesting opportunities often sit just outside the headlines, so do not miss the chance to broaden your watchlist.

• Spot potential upside early by scanning screener containing 21 high quality undiscovered gems with strong fundamentals that have not yet attracted widespread attention.
• Strengthen your core holdings by reviewing the solid balance sheet and fundamentals stocks screener (46 results) that pair resilience with underlying business quality.
• Reduce portfolio stress by checking 66 resilient stocks with low risk scores that score well on key risk indicators while still offering equity exposure.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.